PMID- 27604635
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20220318
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 34
IP  - 6
DP  - 2016 Dec
TI  - A retrospective analysis of 14 consecutive Chinese patients with unresectable or 
      metastatic alveolar soft part sarcoma treated with sunitinib.
PG  - 701-706
AB  - Background The study was aim to assess the efficacy and safety of sunitinib on 14 
      Chinese patients with locally unresectable or metastatic Alveolar Soft Part 
      Sarcoma (ASPS) at two institutions retrospectively. Methods Patients were treated 
      with 37.5 mg of sunitinib once daily continuously without a scheduled 
      off-treatment period. Dose holds or reductions were recommended for grade 3 AEs 
      but were required for grade 4 AEs. Restarting treatment of sunitinib was allowed 
      when AEs returned back to grade 1 or disappeared. The treatment was continued 
      until progression disease (PD), unacceptable toxicity or death. Results From 
      January 2011 to December 2015, 14 patients with unresectable or metastatic ASPS 
      received sunitinib treatment. Among them, 4 patients achieved partial remission 
      (PR), and 10 patients achieved stable disease (SD). Median progression free 
      survival (PFS) was 41.0 months (95 % CI: 7.7 to 74.4 month). Median overall 
      survival (OS) was not reached. The 1- and 4-year OS rates were 90.0 % and 60.0 % 
      respectively. Two patients with primarily unresectable ASPS received complete 
      surgical resection after neoadjuvant treatment of sunitinib. The majority of 
      toxicities encountered were grade 1 or 2 and manageable. The most common adverse 
      events (AEs) were bleeding (35.7 %), hair & skin color change (37.5 %) and 
      mucositis (28.6 %). Conclusions Sunitinib is effective in locally unresectable or 
      metastatic ASPS with a good safety profile. Neoadjuvant treatment with sunitinib 
      improves the chance of resection for patients with locally advanced ASPS.
FAU - Li, Ting
AU  - Li T
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Medical Oncology, Kashgar Prefecture Second People's Hospital, 
      XinJiang, China.
FAU - Wang, Huijie
AU  - Wang H
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Zhang, Shujuan
AU  - Zhang S
AD  - Department of Medical Oncology, Kashgar Prefecture Second People's Hospital, 
      XinJiang, China.
FAU - Atikan Kawuli
AU  - Atikan Kawuli
AD  - Department of Medical Oncology, Kashgar Prefecture Second People's Hospital, 
      XinJiang, China.
FAU - Zhang, Xiaowei
AU  - Zhang X
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Luo, Zhiguo
AU  - Luo Z
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China. luozhiguo88@aliyun.com.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China. luozhiguo88@aliyun.com.
AD  - Department of Medical Oncology, Kashgar Prefecture Second People's Hospital, 
      XinJiang, China. luozhiguo88@aliyun.com.
FAU - Wang, Chunmeng
AU  - Wang C
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China. cmwang1975@163.com.
AD  - Department of Gastric Cancer and Soft Tissue Sarcomas, Fudan University Shanghai 
      Cancer Center, Shanghai, China. cmwang1975@163.com.
LA  - eng
PT  - Journal Article
DEP - 20160908
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bone Neoplasms/*drug therapy/secondary
MH  - China
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Neoadjuvant Therapy
MH  - Prognosis
MH  - Pyrroles/*therapeutic use
MH  - Retrospective Studies
MH  - Sarcoma, Alveolar Soft Part/*drug therapy/pathology
MH  - Sunitinib
MH  - Survival Rate
MH  - Young Adult
OTO - NOTNLM
OT  - Alveolar soft part sarcoma
OT  - Sunitinib
OT  - Target therapy
EDAT- 2016/09/09 06:00
MHDA- 2018/01/05 06:00
CRDT- 2016/09/09 06:00
PHST- 2016/07/02 00:00 [received]
PHST- 2016/09/02 00:00 [accepted]
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
PHST- 2016/09/09 06:00 [entrez]
AID - 10.1007/s10637-016-0390-3 [pii]
AID - 10.1007/s10637-016-0390-3 [doi]
PST - ppublish
SO  - Invest New Drugs. 2016 Dec;34(6):701-706. doi: 10.1007/s10637-016-0390-3. Epub 
      2016 Sep 8.